Biogen Idec Inc 

BIIB:NASDAQ

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
296.49 -10.26   -3.34%0.00%1,457,8831.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

As of 12:25 PM ET 4/24/2014

Latest News Headlines for Biogen Idec Inc

Biogen Idec First Quarter 2014 Revenues Reach -3-

items (37.0) (11.7) ------ ------ Non-GAAP net income attributable to Biogen Idec Inc. $ 586.9 $ 469.4

Biogen Idec First Quarter 2014 Revenues Reach -2-

This press release contains forward-looking statements, including statements about 2014 financial guidance, anticipated regulatory decisions and data read-outs, and potential product launches and timing thereof. These forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "project," "target," "will" and other words and terms of similar meaning. You should not place undue reliance on these statements.

Biogen Idec First Quarter 2014 Revenues Reach $2.1 Billion Driven by Continued Strength of MS Franchise

Quarter Highlighted by EU Approval of TECFIDERA(R) and US and Canadian Approval of New Hemophilia B Therapy ALPROLIX(TM) Neurology Pipeline Expands through Alzheimer's Disease Collaboration with Eisai

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...
Bid/SizeAsk/Size
-- / ---- / --
Price OpenPrevious Close
307.00306.75
Day HighDay Low
308.72286.48
52wk High/Date52wk Low/Date
358.89 / 3/19/2014194.66 / 6/21/2013
% off 52wk High% off 52wk Low
-17.39%52.31%
Beta (5 Yr)Market Capitalization
1.270.1B Large Cap
Shares OutstandingVolatility Avg
236.4M37.76
EPS(TTM)P/E Ratio
8.0436.9
Dividend AnnouncementDividend Yield
--0.00%
Ex-DateDate of Record
----
PayablePayable Date
0.00 - ----

Last Trade as of 4/24/2014 12:21 PM ET

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
9.72%
Johnson & Johnson
9.42%
Pfizer Inc.
0.95%
Merck & Co., Inc.
14.89%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.63%
Pfizer Inc.
3.36%
Merck & Co., Inc.
3.06%
BIIB
Biogen Idec Inc
-3.34%
Johnson & Johnson
0.00%
Pfizer Inc.
-0.74%
Merck & Co., Inc.
0.36%
Compare these stocks